We generate our own conviction in bold ideas that have the potential to dramatically improve human health. The portfolio companies are led by scientist CEOs, and operate virtually and with consultants/CROs to start, and we provide central resources (for example AI for drug discovery, legal, accounting, and HR).
We have launched companies in the fields of cardiovascular disease, neuroscience, oncology, and kidney disease.

Antibody therapeutics for cardiovascular disease

Small molecules for chronic kidney disease

Drug conjugates for multiple myeloma and prostate cancer

Modulating ion channels for Parkinson’s disease